U.S Code last checked for updates: Nov 22, 2024
All TitlesTitle 42Chapter 6ASubchapter IIIPart B
§ 284q.
Pain research
(a)
Research initiatives
(1)
In general
(2)
Annual recommendations
(3)
Definition
(b)
Interagency Pain Research Coordinating Committee
(1)
Establishment
(2)
Membership
(A)
In general
The Committee shall be composed of the following voting members:
(i)
Not more than 7 voting Federal representatives appoint 1
1
 So in original. Probably should be “appointed”.
by the Secretary from agencies that conduct pain care research and treatment.
(ii)
12 additional voting members appointed under subparagraph (B).
(B)
Additional members
The Committee shall include additional voting members appointed by the Secretary as follows:
(i)
6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals.
(ii)
6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.
(C)
Nonvoting members
(3)
Chairperson
(4)
Meetings
(5)
Duties
The Committee shall—
(A)
develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration;
(B)
identify critical gaps in basic and clinical research on—
(i)
the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain;
(ii)
the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and
(iii)
risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; and
(C)
make recommendations to the Director of NIH—
(i)
to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort;
(ii)
on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and
(iii)
on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.
(6)
Report
(7)
Review
(July 1, 1944, ch. 373, title IV, § 409J, as added Pub. L. 111–148, title IV, § 4305(b), Mar. 23, 2010, 124 Stat. 585; amended Pub. L. 115–271, title VII, § 7042, Oct. 24, 2018, 132 Stat. 4016.)
cite as: 42 USC 284q
© 2014 CustomsMobile | Disclaimer | Privacy | About